CREDIT SUISSE AG

(Incorporated in Switzerland)

THIRD SUPPLEMENT DATED 6 NOVEMBER 2020

TO CREDIT SUISSE AG REGISTRATION DOCUMENT DATED 14 MAY 2020

This supplement (the "**Third Supplement**") dated 6 November 2020 supplements the Registration Document dated 14 May 2020 and approved by the Financial Conduct Authority (the "**FCA**") on 14 May 2020 (the "**Registration Document**"). This Third Supplement should be read in conjunction with the Registration Document, the first supplement to the Registration Document dated 5 August 2020 (the "**First Supplement**") and the second supplement to the Registration Document dated 26 October 2020 (the "**Second Supplement**"), including the documents incorporated by reference therein. The terms used in this Third Supplement have the same meaning as the terms used in the Registration Document.

This Third Supplement has been produced to (i) incorporate by reference the Form 6-K Dated 29 October 2020 (as defined below); and (ii) update the sections headed "5. Change" and "10. Legal and Arbitration Proceedings" in the Registration Document.

Document incorporated by reference

This Third Supplement incorporates by reference the following document:

 the Form 6-K of the Group and the Bank filed with the United States Securities and Exchange Commission on 29 October 2020 (the "Form 6-K Dated 29 October 2020") which contains the Credit Suisse Financial Report 3Q20 attached as an exhibit thereto, as indicated in the cross-reference table below (pages 2 to 3).

For ease of reference, the relevant information from the Form 6-K Dated 29 October 2020 can be found on the following pages of the document:

Section Number	Section Heading	Sub-heading	Page(s)
	Form 6-K [Dated 29 October 2020	
	Form 6-K	Cover Page	1
		Explanatory note	2
		Forward-looking statements	2
		Group and Bank differences	3 to 4
		Selected financial data - Bank	4 to 5
		Exhibits	6
Exhib	it to the Form 6-K Dated 29 Oct	ober 2020 (Credit Suisse Financial Repo	ort 3Q20)
		Cover page	not paginated
		Key metrics	not paginated
		Table of contents	1
		Credit Suisse at a glance	2
1	Credit Suisse results	Credit Suisse results	3
		Operating environment	4 to 6
		Credit Suisse	7 to 17
		Swiss Universal Bank	18 to 24
		International Wealth Management	25 to 31
		Asia Pacific	32 to 35
		Investment Bank	36 to 38
		Corporate Center	39 to 41
		Assets under management	42 to 44
II	Treasury, risk, balance sheet and off-balance sheet	Treasury, risk, balance sheet and off- balance sheet	45
		Liquidity and funding management	46 to 50
		Capital management	51 to 59
		Risk management	60 to 68
		Balance sheet and off-balance sheet	69 to 70
III	Condensed consolidated financial statements – unaudited	Condensed consolidated financial statements – unaudited	71
		Notes to the condensed consolidated financial statements – unaudited	72
		Report of Independent Registered Public Accounting Firm	73

Condensed consolidated financial statements – unaudited	75 to 157
(Includes the consolidated balance sheet, income statement and cash-flow statement of Credit Suisse Group AG)	
Notes to the condensed consolidated financial statements – unaudited, including under Note 34	83 to 157
Certain consolidated income statement and balance sheet information of Credit Suisse AG	152 to 157
List of abbreviations	158
Cautionary statement regarding forward-looking information	161

The information identified in the above table is incorporated by reference into, and forms part of, the Registration Document (and any information not listed in the above table but included in the document referred to in the above table is not incorporated by reference and either (a) is covered elsewhere in the Registration Document; or (b) is not relevant for investors).

This supplement incorporates by reference the Form 6-K Dated 29 October 2020.

A copy of the document incorporated by reference specified above can be inspected online at:

- <u>https://www.credit-suisse.com/media/assets/corporate/docs/about-us/investor-relations/financial-</u> disclosures/sec-filings/2020-q3-6k-group-bank-2910.pdf (the Form 6-K Dated 29 October 2020).

Only the specified portions of such document have been incorporated by reference into the Registration Document, and not, for the avoidance of doubt, any other parts of the websites referred to in the Registration Document, including this Third Supplement.

Save as disclosed in the First Supplement, the Second Supplement and this Third Supplement, no other significant new factor, material mistake or inaccuracy relating to information included in the Registration Document has arisen or been noted, as the case may be, since the publication of the Registration Document.

Change

Apart from the uncertainty relating to the impact of the ongoing global COVID-19 pandemic disclosed in the Registration Document (as supplemented), including in (i) "Risk Factors—2. Market and Credit Risks—2.1 The ongoing global COVID-19 pandemic has adversely affected, and may continue to adversely affect, our business, operations and financial performance" and (ii) the sections of the Credit Suisse Financial Report 3Q20 headed "I – Credit Suisse results—Operating environment" (on pages 4 to 6), "I – Credit Suisse results—Credit Suisse—Other information—COVID-19 and related regulatory measures" (on page 14) and "II – Treasury, risk, balance sheet and off-balance sheet—Risk management—Overview and risk-related developments—Key risk developments" (on page 60), there has been no significant change in the financial position of Credit Suisse AG and its consolidated subsidiaries since 30 September 2020.

Apart from the uncertainty relating to the impact of the ongoing global COVID-19 pandemic disclosed in the Registration Document (as supplemented), including in (i) "Risk Factors—2. Market and Credit Risks—2.1 The ongoing global COVID-19 pandemic has adversely affected, and may continue to adversely affect, our business, operations and financial performance" and (ii) the sections of the Credit Suisse Financial Report 3Q20 headed "I – Credit Suisse results—Operating environment" (on pages 4 to 6), "I – Credit Suisse results—Credit Suisse—Other information—COVID-19 and related regulatory measures" (on page 14) and "II – Treasury, risk, balance sheet and off-balance sheet—Risk management—Overview and risk-related developments—Key risk

developments" (on page 60), there has been no significant change in the financial performance of Credit Suisse AG and its consolidated subsidiaries since 30 September 2020 to the date of the document.

Apart from the uncertainty relating to the impact of the ongoing global COVID-19 pandemic disclosed in the Registration Document (as supplemented), including in (i) "Risk Factors—2. Market and Credit Risks—2.1 The ongoing global COVID-19 pandemic has adversely affected, and may continue to adversely affect, our business, operations and financial performance" and (ii) the sections of the Credit Suisse Financial Report 3Q20 headed "I – Credit Suisse results—Operating environment" (on pages 4 to 6), "I – Credit Suisse results—Credit Suisse— Other information—COVID-19 and related regulatory measures" (on page 14) and "II – Treasury, risk, balance sheet and off-balance sheet—Risk management—Overview and risk-related developments—Key risk developments" (on page 60), there has been no material adverse change in the prospects of Credit Suisse AG and its consolidated subsidiaries since 31 December 2019.

Legal and Arbitration Proceedings

Except as disclosed in the Annual Report 2019 under the heading "Litigation" (note 39 to the condensed consolidated financial statements of Credit Suisse Group AG) on pages 376 to 387, the Form 6-K Dated 7 May 2020 under the heading "Litigation" (note 32 to the condensed consolidated financial statements of Credit Suisse Group AG on pages 155 to 156 of the exhibit (Credit Suisse Financial Report 1Q20) to the Form 6-K Dated 7 May 2020), in the Form 6-K Dated 30 July 2020 under the heading "Litigation" (note 32 to the condensed consolidated financial statements of Credit Suisse Group AG on pages 161 to 163 of the exhibit (Credit Suisse Group AG on pages 161 to 163 of the exhibit (Credit Suisse Financial Report 2Q20) to the Form 6-K Dated 30 July 2020) and in the Form 6-K Dated 29 October 2020 under the heading "Litigation" (note 33 to the condensed consolidated financial statements of Credit Suisse Financial Report 3Q20) to 151 of the exhibit (Credit Suisse Financial Report 3Q20) to the Form 6-K Dated 29 October 2020 under the heading "Litigation" (note 33 to the condensed consolidated financial statements of Credit Suisse Group AG on pages 150 to 151 of the exhibit (Credit Suisse Financial Report 3Q20) to the Form 6-K Dated 29 October 2020, there are no, and have not been during the period of 12 months ending on the date of this Third Supplement, governmental, legal or arbitration proceedings which may have, or have had in the recent past, significant effects on the Bank's financial position or profitability, and Credit Suisse AG is not aware of any such proceedings being either pending or threatened.

To the extent that there is any inconsistency between (a) any statement in this Third Supplement or any statement or information incorporated by reference into this Third Supplement and (b) any statement or information in or incorporated by reference into the Registration Document as supplemented by the First Supplement and the Second Supplement, the statements or information in (a) above will prevail.

Credit Suisse AG takes responsibility for the Registration Document, as supplemented by the First Supplement, the Second Supplement and this Third Supplement. To the best knowledge of Credit Suisse AG, the information contained in the Registration Document, as supplemented by the First Supplement, the Second Supplement, and this Third Supplement, is in accordance with the facts and the Registration Document, as supplemented by the First Supplement, as supplemented by the First Supplement, the Second Supplement and this Third Supplement, as supplemented by the First Supplement, the Second Supplement and this Third Supplement makes no omission likely to affect its import. This Third Supplement is not for use in, and may not be delivered to or inside, the United States.